Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152 Reese, 1997, HER-2/neu signal transduction in human breast and ovarian cancer, Stem Cells, 15, 1, 10.1002/stem.150001 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Kelley, 1992, Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments, Biochemistry, 31, 5434, 10.1021/bi00139a003 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Vogel, 2001, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J Clin Oncol, 20, 719, 10.1200/JCO.20.3.719 Baselga, 2005, Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule, J Clin Oncol, 23, 2162, 10.1200/JCO.2005.01.014 Marty, 2005, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol, 23, 4265, 10.1200/JCO.2005.04.173 Piccart-Gebhart, 2005, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 353, 1659, 10.1056/NEJMoa052306 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Eiermann, 2001, Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data, Ann Oncol, 12, S57, 10.1093/annonc/12.suppl_1.S57 Smith, 2007, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, Lancet, 369, 29, 10.1016/S0140-6736(07)60028-2 Perez, 2007, Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer, Proc Soc Am Clin Oncol, 25, 512, 10.1200/jco.2007.25.18_suppl.512 Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: first interim analysis. 28th San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 7–10, 2005. Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis. 32nd San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 9–13, 2009. Abstr 62. Suter, 2007, Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial, J Clin Oncol, 25, 3859, 10.1200/JCO.2006.09.1611 Pocock, 1975, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial, Biometrics, 31, 103, 10.2307/2529712 Cox, 1972, Regression models and life-tables, J R Stat Soc Ser B, 34, 187 Shuster, 1991, Median follow-up in clinical trials, J Clin Oncol, 9, 191, 10.1200/JCO.1991.9.1.191 Gray, 1988, A class of K-sample tests for comparing the cumulative incidence of a competing risk, Ann Statist, 16, 1141, 10.1214/aos/1176350951 Snapinn, 2005, Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator, Am Stat, 59, 301, 10.1198/000313005X70371 Perez EA, Suman VJ, Davidson NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. 32nd San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 10–13, 2009. Abstr 80. Rastogi, 2007, Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) compared to AC→T with trastuzumab (H), Proc Soc Am Clin Oncol, 25, LBA513, 10.1200/jco.2007.25.18_suppl.lba513 Seidman, 2002, Cardiac dysfunction in the trastuzumab clinical trials experience, J Clin Oncol, 20, 1215, 10.1200/JCO.20.5.1215